CANTOS Trial Brings Unexpected CVD Promise For Novartis & Regeneron

 
• By Sten Stovall
cardiovascular system
Novartis said the CANTOS trial in inflammatory cardiovascular disease met the primary endpoint • Source: Shutterstock

More from Clinical Trials

More from R&D